A SINGLE DOSE PLACEBO CONTROLLED PHASE I STUDY OF THE FULLY HUMAN ANTI-TNF ANTIBODY D2E7 IN PATIENTS WITH RHEUMATOID ARTHRITIS

Leo B. A. Van De Putte,Piet L. C. M. van Riel,Alfons A. den Broeder,Oliver Sander,Rolf Rau,Christina Binder,Klaus Krüger,M. Schattenkirchner,Helmut Fenner,Jochen Salfeld,Yvonne Bankmann,Hartmut Kupper,Joachim Kempeni

A SINGLE DOSE PLACEBO CONTROLLED PHASE I STUDY OF THE FULLY HUMAN ANTI-TNF ANTIBODY D2E7 IN PATIENTS WITH RHEUMATOID ARTHRITIS

1998

Leo B. A. Van De Putte
Piet L. C. M. van Riel
Alfons A. den Broeder
Oliver Sander
Rolf Rau
Christina Binder
Klaus Krüger
M. Schattenkirchner
Helmut Fenner
Jochen Salfeld
Yvonne Bankmann
Hartmut Kupper
Joachim Kempeni

Abstract 148Objective:The study was performed to determine the safety profile as well as the pharmacokinetics of D2E7, a new fully human anti-TNF antibody. In addition the clinical efficacy in terms of onset, duration and magnitude of response was scored by the DAS.Methods:120 patients with a mean d

Keywords:

Antibody d2e7
Medicine
Diabetes mellitus
Placebo
Rheumatoid arthritis
Antibody
in patient
Internal medicine
Gastroenterology
Tumor necrosis factor alpha
Pharmacokinetics
Immunology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations